Scholarlink

<p>Bone defects remain a substantial clinical burden. Exosomes have been extensively investigated as cell-free therapeutic candidates, exhibiting favorable biocompatibility and potential applicability in bone defect repair. Mechanisms relevant to bone regeneration are delineated, including activation of osteogenic and angiogenic programs, modulation of osteoblast–osteoclast coupling, immune regulation, and extracellular matrix remodeling. Engineering strategies that enhance targeting, stability, and potency are summarized. Delivery platforms that provide spatial and temporal control of release at defect sites are also appraised. Artificial intelligence (AI) has been examined as an accelerator of translation. Applications include high‑fidelity exosome characterization, data‑driven biomaterial and formulation design, and prediction of therapeutic response from multimodal data. Large language models further assist evidence synthesis and hypothesis generation. Persistent barriers include heterogeneity in isolation and analytics, low yield and limited scalability, lack of standardization, and insufficient validation in disease‑relevant and large‑animal models. A forward agenda emphasizes standardized manufacturing and quality control, mechanism‑informed cargo and surface engineering, responsive delivery systems and AI‑enabled design–control pipelines to realize precise and reproducible exosome therapies for complex bone defects.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exosome-enabled bone defect repair: mechanistic foundations, bioengineered delivery, and artificial intelligence-driven translation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月1日

查看全文
  • Shen Yang,
  • Siliang Ge,
  • Zhongyang Liu,
  • Junyu Chen,
  • Feifan Chang,
  • Junmin Shen,
  • Fanfeng Wu,
  • Xinyu Sun,
  • Zhongqi Wang,
  • Yi Li,
  • Mingming Zhang,
  • Ruijing Chen,
  • Taojin Feng,
  • Tao Yin,
  • Pincong Fu,
  • Ming Chen,
  • Pengbin Yin,
  • Libo Hao

摘要

Bone defects remain a substantial clinical burden. Exosomes have been extensively investigated as cell-free therapeutic candidates, exhibiting favorable biocompatibility and potential applicability in bone defect repair. Mechanisms relevant to bone regeneration are delineated, including activation of osteogenic and angiogenic programs, modulation of osteoblast–osteoclast coupling, immune regulation, and extracellular matrix remodeling. Engineering strategies that enhance targeting, stability, and potency are summarized. Delivery platforms that provide spatial and temporal control of release at defect sites are also appraised. Artificial intelligence (AI) has been examined as an accelerator of translation. Applications include high‑fidelity exosome characterization, data‑driven biomaterial and formulation design, and prediction of therapeutic response from multimodal data. Large language models further assist evidence synthesis and hypothesis generation. Persistent barriers include heterogeneity in isolation and analytics, low yield and limited scalability, lack of standardization, and insufficient validation in disease‑relevant and large‑animal models. A forward agenda emphasizes standardized manufacturing and quality control, mechanism‑informed cargo and surface engineering, responsive delivery systems and AI‑enabled design–control pipelines to realize precise and reproducible exosome therapies for complex bone defects.

Graphical abstract